Vargas-Uricoechea Hernando, Bonelo-Perdomo Anilza
Division of Endocrinology and Metabolism, Internal Medicine Department, Universidad del Cauca, Carrera 6 No. 13N-50, Popayán, Cauca, Colombia.
Division of Basic Immunology and Biomedical Sciences, Universidad del Valle-Campus San Fernando, Calle 4 B No. 36-00 Edificio 116 - Oficina 3001 (Tercer piso), Cali, Valle, Colombia.
Curr Heart Fail Rep. 2017 Feb;14(1):48-58. doi: 10.1007/s11897-017-0312-5.
The purpose of this review is to provide an update on the current knowledge of the pathophysiology, the mechanisms, and the cardiovascular impact of the different stages of thyroid dysfunction (TD) in heart failure (HF) patients.
The influence of thyroid hormones (THs) on the cardiovascular system involves the regulation of key processes related to maintenance of cardiac function; however, there are no long-term studies available showing that intervening the TD changes the incidence or the prognosis in HF individuals. Future research shall focus on the effects of cardiovascular morbidity and mortality associated with different treatment modalities for hyper and hypothyroidism. TD has been associated with different clinical results in HF individuals; treatment with THs in patients with hypothyroidism improves cardiovascular risk factors, but the effect on cardiovascular events has not been assessed in randomized, controlled trials.
本综述旨在更新目前关于心力衰竭（HF）患者甲状腺功能障碍（TD）不同阶段的病理生理学、机制及心血管影响的知识。
甲状腺激素（THs）对心血管系统的影响涉及维持心脏功能相关关键过程的调节；然而，尚无长期研究表明干预TD可改变HF患者的发病率或预后。未来研究应聚焦于甲亢和甲减不同治疗方式相关的心血管发病率和死亡率的影响。TD与HF患者的不同临床结果相关；甲状腺功能减退患者使用THs治疗可改善心血管危险因素，但对心血管事件的影响尚未在随机对照试验中进行评估。
